NCT04865497 - Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old | Biotech Hunter

Enrollment

1,050

Participants

Timeline

Start Date

January 19, 2019

Primary Completion Date

December 7, 2019

Study Completion Date

December 31, 2020

Conditions

DysenteryDysentery, Bacillary

Interventions

BIOLOGICAL

S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine

Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

BIOLOGICAL

S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine

Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

BIOLOGICAL

S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine

Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

BIOLOGICAL

Haemophilus b Conjugate Vaccine

Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.

Trial Locations (1)

530000

Quanzhou Center for Disease Control and Prevention, Quanzhou

All Listed Sponsors

lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY